Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03766958 · ClinicalTrials.gov registry record
A Registry to Evaluate the Performance of the BDX-XL2 Test
A clinical trial, sponsored by Biodesix.
- Completed
- Registry status
- 842
- Enrollment target
NCT03766958: Completed study, sponsored by Biodesix.
NCT03766958 is a clinical trial that has completed, run by Biodesix. The registered enrollment target is 842 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03766958 has completed, sponsored by Biodesix.
- COMPLETED
- Registry status
- 842 participants
- Enrollment target
Study Summary
The purpose of the ORACLE Registry is to demonstrate clinical utility of the BDX-XL2 test; specifically, the potential to reduce unnecessary invasive procedures, such as biopsies and surgeries, on benign lung nodules while not significantly increasing the number of malignant lung nodules routed to CT surveillance. Clinical data will be collected from participating patients to evaluate the impact of the BDX-XL2 test when used in the clinical management of recently identified lung nodules assessed to have a low to moderate risk of cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 842 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2024-05-23 |
What the finished NCT03766958 record still lists
NCT03766958 is an observational study that tracks outcomes without assigning an intervention. The registered 842 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03766958 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03766958 about?
NCT03766958 is a clinical study titled "A Registry to Evaluate the Performance of the BDX-XL2 Test". The purpose of the ORACLE Registry is to demonstrate clinical utility of the BDX-XL2 test; specifically, the potential to reduce unnecessary invasive procedures, such as biopsies and surgeries, on benign lung nodules while not significantly increasing the number of malignant lung nodules routed to C...
What is the current status of trial NCT03766958?
This trial is currently completed. The enrollment target is 842 participants. The study started on 2018-10-16. Estimated completion is 2024-05-23.
Who is sponsoring clinical trial NCT03766958?
This trial is sponsored by Biodesix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06027788 · 842 participants · NA
CTSN Embolic Protection Trial
- NCT06439979 · 843 participants · NA
Rural Adult and Youth Sun Protection Study
- NCT06747949 · 844 participants · Phase 3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI